- Home
- AKTX vs KPLT Comparison
AKTX vs KPLT Comparison
Compare AKTX & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- KPLT
- Stock Information
- Founded
- AKTX N/A
- KPLT 2012
- Country
- AKTX United States
- KPLT United States
- Employees
- AKTX N/A
- KPLT N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- KPLT Diversified Commercial Services
- Sector
- AKTX Health Care
- KPLT Consumer Discretionary
- Exchange
- AKTX Nasdaq
- KPLT Nasdaq
- Market Cap
- AKTX 35.7M
- KPLT 34.5M
- IPO Year
- AKTX N/A
- KPLT N/A
- Fundamental
- Price
- AKTX $1.08
- KPLT $9.22
- Analyst Decision
- AKTX
- KPLT Hold
- Analyst Count
- AKTX 0
- KPLT 2
- Target Price
- AKTX N/A
- KPLT $12.00
- AVG Volume (30 Days)
- AKTX 22.7K
- KPLT 24.0K
- Earning Date
- AKTX 08-18-2025
- KPLT 08-13-2025
- Dividend Yield
- AKTX N/A
- KPLT N/A
- EPS Growth
- AKTX N/A
- KPLT N/A
- EPS
- AKTX N/A
- KPLT N/A
- Revenue
- AKTX N/A
- KPLT $254,079,000.00
- Revenue This Year
- AKTX N/A
- KPLT $22.26
- Revenue Next Year
- AKTX N/A
- KPLT $11.03
- P/E Ratio
- AKTX N/A
- KPLT N/A
- Revenue Growth
- AKTX N/A
- KPLT 9.72
- 52 Week Low
- AKTX $0.85
- KPLT $5.08
- 52 Week High
- AKTX $4.40
- KPLT $21.88
- Technical
- Relative Strength Index (RSI)
- AKTX 41.09
- KPLT 67.82
- Support Level
- AKTX $1.10
- KPLT $7.95
- Resistance Level
- AKTX $1.15
- KPLT $10.59
- Average True Range (ATR)
- AKTX 0.03
- KPLT 0.61
- MACD
- AKTX 0.00
- KPLT 0.25
- Stochastic Oscillator
- AKTX 10.00
- KPLT 96.27
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.